TransCode Therapeutics, Inc. (RNAZ)

0.8200 +0.1130 (+15.98%) At close: 04:00PM EDT

TransCode Therapeutics, Inc.

6 Liberty Square
Suite 2382
Boston, MA 02109
United States
857 837 3099
https://www.transcodetherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 10

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Thomas A. Fitzgerald M.B.A.	Interim CEO, CFO, President, VP of Administration & Director	358.14k	N/A	1952
Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D.	Executive Chairman of the Board	102.5k	N/A	1959
Dr. Zdravka Medarova Ph.D.	Co-Founder & Chief Scientific Officer	N/A	N/A	1975
Dr. Anna Moore Ph.D.	Co-Founder, Scientific Advisor & Member of Scientific Advisory Board	N/A	N/A	1962
Ms. Susan Duggan M.B.A., R.N.	Senior Vice President of Operations	N/A	N/A	N/A
Dr. Daniel R. Vlock M.D.	Chief Medical Officer	N/A	N/A	1952

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Corporate Governance

TransCode Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.